Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 15/20 | 0.46 |
| ▸ | CNR2 | P34972 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5484604 | 0.76 | CNR1 (0.46) | CNR1CNR2KCNH2 | |
| SCHEMBL5106047 | 0.74 | CNR1 (0.57) | CNR1ALDH1A1MAPTNPSR1 | |
| SCHEMBL5102816 | 0.73 | CNR1 (0.56) | CNR1CNR2KDM4E | |
| SCHEMBL5106096 | 0.71 | CNR1 (0.49) | CNR1CNR2 | |
| SCHEMBL5105634 | 0.66 | CNR1 (0.64) | CNR1CNR2KDM4E | |
| SCHEMBL5103007 | 0.66 | CNR1 (0.60) | CNR1ALDH1A1MAPTHTT | |
| SCHEMBL5111599 | 0.65 | CNR1 (0.54) | CNR1CNR2 | |
| SCHEMBL5103312 | 0.65 | CNR1 (0.54) | CNR1KDM4EALDH1A1MAPT | |
| SCHEMBL5113066 | 0.64 | CNR1 (0.53) | CNR1ALDH1A1MAPTHTTNPSR1 | |
| SCHEMBL5111418 | 0.64 | CNR1 (1.00) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043060-A1 | OXAZOLE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | OXA1L, ARG2, CYP3A7 | CNR1 246/4885CNR2 356/4885KDM4E 2554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.